89 results about "Biological immortality" patented technology

The present invention provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, said methods comprising culturing the precursor cells in the presence of a Notch agonist and one or more growth factors that support the proliferation but not differentiation of the non-terminally differentiated cells. The present invention further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a Notch agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type. The immortalized and / or differentiated cells of the invention can be used to repopulate cell populations that have been diminished, for example as a result of infection or exposure to certain drugs. The invention further provides a cell culture comprising a population of non-terminally differentiated cells immortalized by the methods of the present invention and kits comprising reagents that promote the immortalization of precursor cells. The invention further provides methods for screening for Notch modulators and for identifying genes involved in processes of cellular differentiation.

The present invention provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, said methods comprising culturing the precursor cells in the presence of a Notch agonist and one or more growth factors that support the proliferation but not differentiation of the non-terminally differentiated cells. The present invention further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a Notch agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type. The immortalized and / or differentiated cells of the invention can be used to repopulate cell populations that have been diminished, for example as a result of infection or exposure to certain drugs. The invention further provides a cell culture comprising a population of non-terminaly differentiated cells immortalized by the methods of the present invention and kits comprising reagents that promote the immortalization of precursor cells. The invention further provides methods for screening for Notch modulators and for identifying genes involved in processes of cellular differentiation.

Cell culture conditions for the isolation, maintenance, and indefinite expansion of human glia are established favoring the growth of neural precursor cells. Cultured cells proliferate indefinitely, express catalytic telomerase, and retain a non-immortalized phenotype. Compositions allow for the indefinite expansion of non-immortalized neural tissue for bioassay applications and restorative neuroscience.

The present invention relates to the method of establishing human ovary cancer immortal cell strian, the immortal gene-SV40T antigen gene is introduced into human ovary cancer original generation cell, then screened, resistance clone enlarge culture to obtain immortal cell strain. The established ovary cancer cell strain is named as BVPH:OVSC-2 and is kept by CGMCC with keeping No.0606, its biological characteristics includes strong invading powder, cell is spindle sarcoma call shape, apparent heteromorphism, retains biological characters of original cell.

The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use cells that contain at least some TSAs and / or TAAs that are shared with the antigens present in patients' tumour. In each case, tumour cells are utilised as the starting point on the premise that only tumour cells will contain TSAs or TAAs of relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells as the basis of an allogeneic cell cancer vaccine. Normal cells do not possess TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalised normal cell lines derived from the prostate. The cell lines are lethally irradiated utilising gamma irradiation at 50–300 Gy to ensure that they are replication incompetent prior to use in the mammal or human.

The invention relates to constructs comprising: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) an unpaired splice-donor site. The invention further relates to a method of producing protein in vitro or in vivo comprising the homologous recombination of a construct as described above within a cell. The homologously recombinant cell is then maintained under conditions which will permit transcription and translation, resulting in protein expression. The present invention further relates to homologously recombinant cells, including primary, secondary, or immortalized vertebrate cells, methods of making the cells, methods of homologous recombination to produce fusion genes, methods of altering gene expression in the cells, and methods of making a protein in a cell employing the constructs of the invention.

The invention belongs to the technical field of cell engineering, and particularly relates to a preparation method of an immortalized human cartilage endplate stem cell line and use of the immortalized human cartilage endplate stem cell line. The invention aims to solve the technical problem of providing an effective preparation method for constructing the immortalized human cartilage endplate stem cell line. The technical scheme is as follows: the preparation method for constructing the immortalized human cartilage endplate stem cell line by adopting the lentiviral transfection technology comprises the following steps: a, constructing a SV40T antigen virus vector; b, carrying out gene transfection of a human endplate stem cell on SV40T antigen; and c, passaging and sieving to obtain the immortalized human cartilage endplate stem cell line. The invention further provides the use of the immortalized human cartilage endplate stem cell line prepared by the method in preparation of bone tissue engineering materials. The immortalized human cartilage endplate stem cell line provided by the invention can be applied to preparation of a tissue-engineered bone and clinically provides a seed cell of the bone tissue engineering low in price and strong in osteogenic capability for the patients with a series of long bone defects and bone nonunion.

The invention provides a gene, a vector and a method for preparing immortalized dendritic cells and the immortalized dendritic cells, belonging to the technical field of genetic engineering. The genefor preparing the immortalized dendritic cells is obtained by connecting an ST40 gene with a TAX2 gene through a linker, wherein the nucleotide sequence of the ST40 gene is as shown in SEQ ID No. 1; and the nucleotide sequence of the TAX2 gene is shown as SEQ ID No. 2. The immortalized dendritic cells prepared from the genes provided by the invention comprise HLA-A0201, and covers nearly nine types of common HLA-A1101, HLA-A2402, HLA-A0301 and the like of Chinese population, so the application range is greatly enlarged.

The invention provides an immortalized mouse microglial cell line B6Mi1. A preservation number of the immortalized mouse microglial cell line B6Mi1 in CCTCC (China Center for Type Culture Collection)is CCTCC NO:C2019263, and a preservation date is November 6, 2019. A creation method of the mouse microglial cell line includes steps: a, primary mouse microglial cell separation and culture; b, primary mouse microglial cell purification and cloning. Mouse microglial cells are spontaneous immortalized microglial cells and are in IBA1 positive, CD45<+>CD11b<+>. B6Mi1 cells are highly proliferative,cell cycle analysis shows that more than half of the cells are in an S stage and a G2M stage, and cell doubling time is 14 hours. By LPS processing, expression of inflammatory factors including TNFalpha, IL-1beta, IL-6, iNOS and the like can be remarkably increased. According to the results, the B6Mi1 cells belong to the mouse microglial cell line with microglia cell phenotype and biological characteristics, and the cell line can be used for researching biological characteristics of the microglial cell and neuroinflammation and screening and development of related medicines.

The present disclosure provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, the methods comprising culturing the precursor cells in the presence of a Notch 1 agonist, Notch 2 agonist or Notch 1 agonist and Notch 2 agonist (and, in particular embodiments, one or more growth factors) that support the proliferation but not differentiation of the non-terminally differentiated cells. The present disclosure further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a Notch 1 agonist, Notch 2 agonist or Notch 1 agonist and Notch 2 agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type. The immortalized and / or differentiated cells of the disclosure can be used to repopulate cell populations that have been diminished, for example as a result of infection or exposure to certain drugs. The disclosure further provides a cell culture comprising a population of non-terminally differentiated cells immortalized by the methods of the present disclosure and kits comprising reagents that promote the immortalization of precursor cells.

Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumour specific antigens ("TSAs") and / or tumour associated antigens ("TAAs") having shared identity with antigens in a targeted tumour. In such cases, tumour cells often are utilised as a starting point on the premise that only tumour cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells, in combination with primary and / or metastatic tumour cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and / or metastatic tumour cells. More surprisingly, a three way combination of cells obtained from metastasised cells, non metastasised tumour and cells from a normal cell line provided good therapy. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalised normal cell lines derived from the prostate according to parameters described herein. The cell lines may be lethally irradiated with, for example, gamma irradiation at 50-300 Gy to ensure that they are replication incompetent prior to use.